Kornimate/medical-research-clean huggingface dataset:
using immersive virtual reality to treat complex regional pain syndrome in adults

Conditions: Pain, Chronic

Summary: this study is designed to test if the use of virtual reality (vr) can improve chronic pain related to crps. one way is to use virtual reality. virtual reality involves looking into a set of goggles and interacting with a computer-simulated world. the use of vr has been shown to be an effective treatment for other pain conditions (hoffman et al., 2019) and is inexpensive and noninvasive.

participants will "go into" simple fun pain distracting virtual reality worlds (no previous video game experience needed) that encourages physical movement of the injured limb (e.g., their injured hand). they will also learn some simple daily 10 minute stress reduction, mood lifting mindfulness skills in vr and will receive audio instructions to focus their attention on the sights and sounds, and controlled breathing (flores et al., 2019).

Eligibility criteria:
inclusion criteria * adults (18+) * confirmed diagnosis of either crps i or crps ii of one or both upper limbs (as defined by the budapest criteria) * average pain score in the affected crps limb(s) greater than or equal to 3 out of 10 * on a stable treatment plan for 4 weeks prior to the vr intervention phase * ability to wear a vr head-mounted display * ability to speak and read english * ability to provide informed consent. exclusion criteria: * personal history of severe motion sickness * severe systemic disease that is a constant threat to life (asa class iv+) * prisoners.

Keywords: chronic pain, complex regional pain syndrome, virtual reality, home based, mindfulness, pain neuroscience education
tear film evaluation of dailies® aquacomfort plus® multifocal and toric

Conditions: Refractive Error

Summary: the purpose of this study is to evaluate the pre lens tear film characteristics of dailies® aqua comfort plus® multifocal (dacp mf) and toric (dacp toric) compared to dailies® aqua comfort plus® sphere (dacp) daily disposable contact lenses over 12 hours of lens wear.

two population groups (presbyopes and astigmats) will be enrolled in the study.

Eligibility criteria:
inclusion criteria: * must sign an informed consent document; * adapted, current soft contact lens wearer with either: 1. a spectacle add between +0.50 and +2.50 (inclusive) \[presbyopes group\] 2. a spherical correction of an astigmatism up to 20% of the amount of the sphere \[astigmats group\]; * contact lens prescription in the power range specified in the protocol; * vision correctable to 0.2 logmar (logarithmic minimal angle for resolution) or better in each eye at distance with pre-study lenses or manifest refraction at visit 1; * willing to wear study lenses up to 12 hours and attend all study visits; * can be successfully fitted with study lenses; * other protocol-specified inclusion criteria may apply. exclusion criteria: * any ocular anterior segment infection, inflammation, abnormality, or active disease that would contraindicate contact lens wear; * use of systemic or ocular medications for which contact lens wear could be contraindicated as determined by the investigator; * use of artificial tears and rewetting drops during the study; * monocular (only 1 eye with functional vision) or fit with only 1 lens; * any abnormal ocular condition observed during the visit 1 slit-lamp examination; * history of herpetic keratitis, ocular surgery, or irregular cornea; * pregnant or lactating; * unstable tear film with a nik-but value below 8 seconds in either eye without lenses; * participation in any clinical study within 30 days of visit 1; * other protocol-specified exclusion criteria may apply.

Keywords: dailies aquacomfort plus® multifocal (dacp mf) dailies aquacomfort plus® toric (dacp toric) tear film stability non-invasive keratograph break-up time (nik-but)
abundance of lactobacillus in endometrium affected by chronic endometritis

Conditions: Non Specific Chronic Endometritis; Infertility, Female

Summary: infertile women undergoing hysteroscopy for diagnostic or therapeutic indication are asked to donate a sample of endometrium. endometrial samples of study participants are examined for signs of chronic endometritis by immunohistochemical analysis. high-throughput sequencing of the microbial 16s ribosomal ribonucleic acid (rrna) subunit is performed to identify and quantify the microbes present in the sample. obstetric and reproductive outcome is recorded 12 months after hysteroscopy (telephone interview).


Eligibility criteria:
inclusion criteria: * infertile (≥ 12 months of unprotected regular intercourse) premenopausal women or women with ≥ 2 consecutive miscarriages undergoing hysteroscopy. - infertile women undergoing office hysteroscopy for other reasons, such as suspected intrauterine adhesions after curettage, irregular endometrium, uterine polyps, repeated implantation failure in assisted reproduction, etc. * signed informed consent * bmi ≥ 18 kg/m2 and ≤ 40 kg/m2 * age: ≥ 18 years and ≤ 45 years * follicle stimulating hormone (fsh) ≤ 20 (day 2-5 and estradiol ≤ 300 pmol/l) exclusion criteria: * treatment with antibiotics in the past 3 months * treatment with immune-suppressing or immune-modulating drugs in the past 3 months * treatment with estrogens, progestins, contraceptives and/or antiestrogenic drugs in the cycle during which hysteroscopy is performed * current infection of the cervix with chlamydia trachomatis and/or gonorrhea * pelvic surgery in the past 3 months * suspicion of malignancy * pregnancy * breast feeding * perimenopause (irregular menses and fsh ≥ 20 u/l on day 3-5 of the cycle) * outdated endometrial sample from the luteal phase (this criterion will be evaluated during visit 4 post surgery) * elevated progesterone concentration ≥ 20 nmol/l measured in the blood sample taken at the time of hsc. * insufficient amount of tissue for immunohistochemical analysis and/or microbial 16s rrna gene sequencing
hyperbaric oxygen therapy can improve cognitive deficits post low grade glioma removal surgery

Conditions: Post Low Grade Glioma Surgery; Cognitive Deficits

Summary: the aim of the current study is to evaluate, in a prospective cross-over, randomized study, the effect of hyperbaric oxygen therapy (hbot) on patients with chronic impairment after low grade glioma tumor removal surgery


Eligibility criteria:
inclusion criteria: * post low grade glioma (who i-ii) removal surgery 3-12 months prior to the inclusion in the study. * all patients have to have persistent cognitive impairment (mindstream score should be at least one sd lower than average) regarding without noticeable improvement during the last month prior to their enrolment. * age 18 years or older. exclusion criteria: * dynamic neurologic/cognitive improvement or worsening during the past month; previous brain radiotherapy and/or radiosurgery. steroids dependence chemotherapy in the past month or scheduled in the next 3 months seizures 1 month previous to inclusion had been treated with hbot for any other reason 1 month prior to inclusion; have any other indication for hbot; chest pathology incompatible with pressure changes; inner ear disease; patients suffering from claustrophobia; inability to sign written informed consent; smoking patients will not be allowed to smoke during the study and if they would not comply with this demand they will be excluded.
changes in vitreous temperature during phacoemulsification

Conditions: Proliferative Diabetic Retinopathy

Summary: temperature in the vitreous cavity decreases during vitrectomy, and the same effect is seen during an uneventful phaco surgery. significant changes occur between the baseline temperature and after every step of the surgery.

a 23-gauge thermometer probe inserted prior to the beginning of the cataract surgery to measure the vitreous temperature at different stages of the procedure (capsulorrhexis, hydrodissection, phacomulsification, irrigation/aspiration and intraocular lens (iol) implantation). room temperature also registered during every step. at the end of the surgery, oral temperature will be measured.

Eligibility criteria:
inclusion criteria: * patients from the retina department that underwent phacoemulsification and vitrectomy exclusion criteria: * posterior capsule rupture

Keywords: cataract phacoemulsification temperature vitreous
an investigational drug study to assess weight loss in patients with type 2 diabetes mellitus (0364-011)(terminated)

Conditions: Obesity Type 2 Diabetes Mellitus; Type 2 Diabetes Mellitus

Summary: a worldwide study with extension in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug for weight loss on body weight.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 27 kg/m2 and 43 kg/m2 and hba1c between 7.0% and 10% exclusion criteria: * history of major psychiatric disorder * blood pressure greater than 160/100 * use of any antihyperglycemic agent other than metformin * triglycerides greater then 600 mg/dl
minocycline in primary sclerosing cholangitis (psc)

Conditions: Primary Sclerosing Cholangitis

Summary: the purpose of the study is to see how safe and effective minocycline is in the treatment of primary sclerosing cholangitis (psc).

the purpose of the study is to determine the safety profile of minocycline in patients with psc and to compare the effects of minocycline on the baseline values of the following parameters: symptoms of pruritus and fatigue, liver biochemistries, mayo risk score, the development of clinical progression and complications of liver disease.

Eligibility criteria:
inclusion criteria: * both genders * females of childbearing age must have negative pregnancy test within 48 hours of participation and agreement to practice contraception for the duration of the study. * age 18 years old and \< than 75 years old. * history of chronic cholestatic disease of at least 6 months duration. * serum alkaline phosphatase level at least 1.5 times the upper limit of normal. * cholangiography demonstrating intrahepatic and/or extrahepatic biliary obstruction, beading, or narrowing consistent with psc. * liver biopsy consistent with the diagnosis of psc. * patient's informed consent for study participation. exclusion criteria: * treatment with tetracyclines, ursodeoxycholic acid, corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil, budesonide, pentoxifylline, pirfenidone, nicotine, tacrolimus, silymarin, vitamin e or prednisone in the preceding three months. * findings highly suggestive of hepatobiliary disease of other etiology complicating psc. * anticipated need for liver transplantation in one year determined by the mayo model with an estimate of \<75% one year survival without transplantation. * recurrent variceal bleeding, presence of ascites, or encephalopathy. * active drug or alcohol use. * pregnancy. * breast-feeding. * serum creatinine over 1.5 mg/dl. * prior history of allergic reactions to antibiotics belonging to the tetracycline family. * any condition that, in the opinion of the investigator, would interfere with the patient's ability to complete the study safely or successfully. * patients with active inflammatory bowel disease (ibd) requiring specific treatment in the preceding three months, except for maintenance therapy with 5-asa compounds, or those individuals who have been involved in a trial evaluating any experimental drug for the treatment of ibd in the preceding three months. * recurrent ascending cholangitis requiring hospitalization in the past year.

Keywords: psc
impact of nmn supplementation on cd4+ t cell recovery in hiv patients with immunological failure

Conditions: Human Immunodeficiency Virus

Summary: this proof-of-concept study aims to investigate the potential impact of supplementing with nicotinamide mononucleotide (nmn), a direct precursor of nad+ on cd4+ t cell recovery in virologically suppressed hiv patients experiencing immunological failure on art. we hypothesize that nmn supplementation will increase intracellular nad+ levels, thereby improving cd4+ t cell function and potentially reversing immunological failure. a small cohort of patients will be recruited to evaluate the primary outcome of change in cd4+ t cell count from baseline to the end of the study period after receiving nmn daily for 12 weeks. secondary outcomes including safety and tolerability, impact on pro-inflammatory markers, increase in nad+ levels, immune activation markers and change in quality of life questionnaire scores. patients will participate in two in person visits including a baseline and end of study with two telephone encounters. patients will take 1,000mg nmn daily for a total of 12 weeks during which they will keep a daily log of doses taken and any side effects experienced. at all visits labs and quality of life questionnaire will be completed with complete physical exam to be done at baseline and end of study visit.


Eligibility criteria:
inclusion criteria: * hiv-infected adults aged 18 years or older * virologically suppressed on art documented with two negative viral loads separated by at least 6 months * confirmed diagnosis of immunological failure (cd4+ t cell count \<350 cells/µl 2 years after effective art initiation) * willing to provide informed consent exclusion criteria: * active opportunistic infections * known allergies or sensitivities to nmn or any components of the nmn supplement * current or recent use of other supplements or medications known to affect nad+ metabolism (niacin, nr, nmnh, etc.) * pregnancy or breastfeeding * significant liver or kidney disease * active malignancy * history of uncontrolled substance abuse * severe medical conditions that might interfere with study participation * unable to consent

Keywords: hiv immunologic failure proof of concept cd4+ t cell recovery immunological non-responders nicotinamide mononucleotide
apatinib for advanced biliary carcinoma

Conditions: Biliary Tract Neoplasms

Summary: this is a phase ii open-label, one-arm, single-center study of apatinib for eligible patients with advanced biliary tract carcinoma after the first-line treatment failure. a total of 55 patients is planned for enrollment. the time for enrollment is from nov 2017 to nov 2020, the the follow-up will be ended after nov 2021. patients in the study would receive oral apatinib 500-750mg qd until progression of disease.


Eligibility criteria:
inclusion criteria: 1. patients age between 18 and 70 years 2. histologically confirmed advanced biliary tract carcinoma (btc) or metastatic btc 3. prior lack of response or intolerance to at least one chemotherapeutic regimens (including gemcitabine). 4. at least one measurable lesion as defined by recist 1.1 5. an eastern cooperative oncology group performance status of 0 to 2 6. life expectancy ≥ 12 weeks 7. for those who received other anti-tumor treatment, the damage should have been restored, with the time interval from last dose of nitroso or mitomycin≥6 weeks and interval from last dose of other cytotoxic drugs, radiation or surgery (the wound should be healed completely) ≥4 weeks. 8. acceptable hematologic, hepatic, and renal function within 7 days from screening： the blood anc count≥1.5x109 /l; hemoglobin ≥ 9.0 g/dl，the blood platelet count≥80 x109 /l, total bilirubin \ 50ml/min 9. women of reproductive age need to take effective contraceptive measures exclusion criteria: 1. with other malignant tumor in 5 years，except for cured cervical carcinoma in situ or basal cell carcinoma. 2. uncontrolled blood pressure on medication (140/90 mmhg); patients with \> grade 1 coronary heart disease, cardiac arrhythmias or cardiac dysfunction 3. symptomatic brain or meningeal metastasis 4. history of uncontrolled seizures, central nervous system dysfunction or mental disorder 5. uncontrolled pleural or peritoneal effusion 6. undergoing dialysis 7. severe or uncontrolled infection 8. with multiple factors that affecting oral administration 9. abnormal coagulation function or those receiving thrombolytics or anticoagulants 10. patients with tendency of gastrointestinal hemorrhage, including active peptic ulcer with fecal occult blood ++, hematemesis or melena within 3 months 11. participation in other drug clinical trials within 4 weeks 12. weight below 40kg 13. urine protein ≥2+

Keywords: biliary tract carcinoma apatinib
effect of myofascial release on function and mobility in patients with tmd and low back pain: a randomized trial

Conditions: Temporomandibular Joint Disorder; Low Back Pain; Myofascial Release

Summary: we aim to compare the effectiveness of mfr and exercise therapy on mobility and function by investigating the effectiveness of the myofascial release technique (mfr), which we will apply to the muscles we choose related to the facial system connection in participants with temporomandibular dysfunction (tmd) and low back pain.

we aim to compare the effectiveness of mfr and exercise therapy on mobility and function by investigating the effectiveness of the myofascial release technique (mfr), which we will apply to the muscles we choose related to the facial system connection in participants with temporomandibular dysfunction (tmd) and low back pain. method and material working group (group a): myofascial release technique will be applied. a total of 10 sessions will be applied for 4 weeks, 3 times a week for the first 2 weeks, and 2 times a week for the next 2 weeks. exercise group (group b): the stretching exercises that we planned to give to the exercise group were planned for the muscles to which we will apply myofascial technique. • control group (group c): no application will be made to the control group. evaluations will be made at the beginning of the study and at the end of 4 weeks. the evaluation parameters to be used are as follows; oswestry low back disability survey, algometer and myotonometry. inclusion criteria: participants aged 18-50 years diagnosed with tmd,persons with a score of 20% or more on the oswestry waist index, and people with low back pain for more than 3 months,persons with mechanical low back pain and lumbar disc herniation without neurological deficits will be included in the study.persons with acute or chronic temporomandibular dysfunction will be included. exclusion criteria; neurological problems,presence of extruded and sequestered lumbar disc herniation,cardiovascular symptoms and circulation problems,infection,fibromyalgia, acute arthritis conditions,those with spinal abnormalities,fracture history, presence of dislocation / subluxation will be excluded

Eligibility criteria:
inclusion criteria: * participants aged 18-50 years diagnosed with tmd * persons with a score of 20% or more on the oswestry waist index, and * people with low back pain for more than 3 months * persons with mechanical low back pain and lumbar disc herniation without neurological deficits will be included in the study. * persons with acute or chronic temporomandibular dysfunction will be included exclusion criteria: * neurological problems, * presence of extruded and sequestered lumbar disc herniation * cardiovascular symptoms and circulation problems, * infection, * fibromyalgia, acute arthritis conditions * those with spinal abnormalities, * fracture history, presence of dislocation / subluxation will be excluded

Keywords: tmj disorder, myofascial release, low back pain
posaconazole for pulmonary fungal infection prophylaxis in hematopoietic stem cell transplantation patients

Conditions: Pulmonary Fungal Infection

Summary: this open, prospective, observational multicenter cohort study aims to evaluate the efficacy, safety as well as the effective serum concentration of posaconazole for prevention of pulmonary fungal infections in patients with hematopoietic stem cell transplantation. the correlation of ugt1a4\*3 genotype and cmin of posaconazole, as well as invasive fungal disease (ifd) breakthrough rates will be utilized to evaluate the efficacy while the safety of posaconazole will be assessed by the overall incidence and severity of adverse events in patients.

this open, prospective, observational multicenter cohort study aims to study the efficacy, safety and effective concentration of posaconazole tablets for prevention of pulmonary fungal infection in patients with hematopoietic stem cell transplantation. a total of 360 hematopoietic stem cell transplantation patients receiving posaconazole tablets are expected to be enrolled. posaconazole tablets will be taken orally from the day of transplantation (300 mg q12h d1) followed by 300 mg qd, until 90 days after transplantation. the total duration of the study is estimated to be 24 months, with each patient participating for an estimated 3 months. the relationships between ugt1a4\*3 genotype and drug serum concentration, ifd incidence, aspergillus infection rate, ifd-related mortality rate, ifd-free survival rate, and overall survival rate will be used to evaluate the effectiveness of posaconazole tablets in preventing invasive pulmonary fungal infection in patients with hematopoietic stem cell transplantation. safety of posaconazole tablet will be validated by the overall incidence and severity of adverse events in patients.

Eligibility criteria:
inclusion criteria: * age ≥ 13 years old * the primary causes of hematopoietic stem cell transplantation include aplastic anemia, acute myeloid leukemia, acute lymphoblastic leukemia, non-hodgkin's lymphoma, or other hematologic diseases in patients pretreated for hematopoietic stem cell transplantation. the types of transplantation include autologous transplantation, syngeneic transplantation, matched sibling donor transplantation, unrelated donor transplantation and haploidentical transplantation * the patients themselves or their authorized clients agree to participate in the clinical study and sign the informed consent exclusion criteria: * those with evidence of active fungal infection within 3 weeks prior to enrollment * allergic to azole drugs * severe abnormal liver function * rifampicin, isoniazid, phenytoin, carbamazepine, and long-acting barbiturates were used in combination during the study * any predictably increased patient risk or other factors that might interfere with the outcome of a clinical trial
a molecular toolkit for the microbial investigation of severe community acquired pneumonia

Conditions: Community Acquired Pneumonia; Respiration Failure; Pneumonia

Summary: severe community acquired pneumonia is common and associated with high mortality. conventional microbiological diagnostics identify pathogens in approximately half of cases, which is inadequate for both clinical and epidemiological purposes. this study applies next-generation sequencing based metagenomic techniques to patients with extremely severe community acquired pneumonia, to investigate the microbiome of severe community acquired pneumonia and evaluate metagenomic approaches as diagnostic tools.


Eligibility criteria:
inclusion criteria: * adults aged 18 or over * admitted to a participating severe respiratory failure centre or icu * admitted due to community acquired pneumonia (cap) according to clinical and radiological criteria * tracheal intubation, receiving mechanical ventilation +/- ecmo * requires bronchoscopy as part of routine diagnostic care plan * bronchoscopy takes place within 72 hours of first admission to hospital exclusion criteria: * any current or previous condition/circumstance that, in the opinion of the investigator or study nurse, may put the individual at risk if participating * patients receiving end of life care * hospitalisation within the previous 28 days (not including pre-ecmo hospitalisation for ecmo patients) * consent or assent not given

Keywords: intensive care extra-corporeal membrane oxygenation (ecmo) severe respiratory infections sequencing metagenome diagnosis